Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
International Journal of Molecular Sciences · 14.11.2023 · 24 (22) · 16288
DOI: 10.3390/ijms242216288 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.11.2023. Verfasst von Amer E Alkhalifa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 720 S. Donahue Dr., Auburn, AL 36849, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cerebrovascular Disorders. Die Arbeit wurde bisher 227-mal zitiert (Crossref) und nennt 266 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.
Themen: Demenz
Abstract (Originalsprache)
The blood–brain barrier (BBB) is a unique and selective feature of the central nervous system’s vasculature. BBB dysfunction has been observed as an early sign of Alzheimer’s Disease (AD) before the onset of dementia or neurodegeneration. The intricate relationship between the BBB and the pathogenesis of AD, especially in the context of neurovascular coupling and the overlap of pathophysiology in neurodegenerative and cerebrovascular diseases, underscores the urgency to understand the BBB’s role more deeply. Preserving or restoring the BBB function emerges as a potentially promising strategy for mitigating the progression and severity of AD. Molecular and genetic changes, such as the isoform ε4 of apolipoprotein E (ApoEε4), a significant genetic risk factor and a promoter of the BBB dysfunction, have been shown to mediate the BBB disruption. Additionally, receptors and transporters like the low-density lipoprotein receptor-related protein 1 (LRP1), P-glycoprotein (P-gp), and the receptor for advanced glycation end products (RAGEs) have been implicated in AD’s pathogenesis. In this comprehensive review, we endeavor to shed light on the intricate pathogenic and therapeutic connections between AD and the BBB. We also delve into the latest developments and pioneering strategies targeting the BBB for therapeutic interventions, addressing its potential as a barrier and a carrier. By providing an integrative perspective, we anticipate paving the way for future research and treatments focused on exploiting the BBB’s role in AD pathogenesis and therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, 720 S. Donahue Dr., Auburn, AL 36849, USA.
ORCID-Profile: Amer E Alkhalifa, Amal Kaddoumi
Förderung
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023). Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies. International Journal of Molecular Sciences, 24(22), 16288. https://doi.org/10.3390/ijms242216288
Vancouver
Alkhalifa AE, Al-Ghraiybah NF, Odum J, Shunnarah JG, Austin N, Kaddoumi A. Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies. International Journal of Molecular Sciences. 2023;24(22):16288. doi:10.3390/ijms242216288
BibTeX
@article{Alkhalifa2023,
author = {Alkhalifa, Amer E and Al-Ghraiybah, Nour F and Odum, Julia and Shunnarah, John G and Austin, Nataleigh and Kaddoumi, Amal},
title = {Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {22},
pages = {16288},
doi = {10.3390/ijms242216288}
}
EUVIMED